Technology
Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
It will be the first time ER-100 technology they claim can reverse aging in cells has been tested on a human.


Glideslope AI-powered market news
No market stories in the last 7 days. The latest coverage is below.

No scored stories in the last 7 days.
| Day | Mood | Stories |
|---|---|---|
| Fri, Oct 9 | — | 0 |
| Thu, Oct 8 | — | 0 |
| Wed, Oct 7 | — | 0 |
| Tue, Oct 6 | — | 0 |
| Mon, Oct 5 | — | 0 |
| Sun, Oct 4 | — | 0 |
| Sat, Oct 3 | — | 0 |
| Fri, Oct 2 | — | 0 |
It will be the first time ER-100 technology they claim can reverse aging in cells has been tested on a human.

EYLEA HD shows sustained vision and anatomical improvements over three years, allowing extended dosing intervals in wAMD patients.
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE